Humagen has been involved in research work associated with a variety of leading edge biological initiatives. Some of our insight and creative viewpoints have touched upon application possibilities typically not considered by traditional theoreticians. Humagen's ability to extend the vision of existing and emerging technologies opens new possibilities for expanding the understanding of basic life processes, and opening new frontiers for the application of that understanding.
VLSA-SV MEMBRANE TECHNOLOGY
Very Large Surface Area-Small Volume (VLSA-SV) permeable and semi-permeable membrane project activity involves investigation of materials capable of maintaining barrier membrane characteristics, while allowing selective high volume bi-directional transport of various compounds across the membrane barrier. Efficient high volume transport requires large effective contact surface areas, occupying as small a physical volume as possible.
VASCULAR PROLIFERATION STIMULATION
Promotion of vascular proliferation within living biological tissue, using a variety of protein angiogenesis factors, has been a process used by cancer cells to develop a more effective nutrient resource for tumor growth. Utilization of these same isolated angiogenic protein and other factors for the stimulation and support of healthy tissue development, presents an opportunity to improve upon the growth and survival rates of tissues grown in cultured environments.
ARTIFICIAL/MECHANICAL MAMMALIAN UTERINE/TISSUE GROWTH MEDIUM MEDICAL DEVICE DESIGN
The rise of mammalian fertility interests and cellular culture growth challenges, including those associated with developing genomic modification and inheritable mammalian medical condition research, has generated a theoretical and practical need for devices within which absolutely controlled and fully isolated environmental cellular growth conditions can be achieved and monitored. High level visualization and design, along with practicable prototyping, modeling and testing of such devices has, and continues to be, a primary focus of the intellectual capacity of our theoreticians and engineers.
CANINE NEUROLOGICAL DISEASE
Granulomatous meningoencephalitis (GME) is an inflammatory condition of unknown etiology primarily affecting the central nervous system of canines. GME may have an an immume system mediated cause, based upon abnormal immune system response to an infectious agent, either viral, bacterial or fungal in nature. Residual vestiges, or some other aspect of the infectious agent, may take up residency in the canine central nervous system and brain tissue, resulting in an adverse immune system reaction. GME is typically classified as disseminated, focal or ocular. Symptoms may be temporarily mitigated by corticosteroidal and other immunosupressive treatment. Average survival time from onset of symptoms is approximately two weeks, and no known cure exists.
"It seems the ultimate objective of the life force is not to make itself unique to any particular form, nor to hold one form superior over another. Rather, life seems to establish its presence in as many variations as possible, in order to guarantee the highest probablility of survival under any change in environmental circumstance." -- Mark Broin